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INTRODUCTION
OBJECTIVE The aim of this review is to discuss
the association between F. nucleatum and CRC
and to highlight the possible mechanisms of
carcinogenesis of this bacterium.
RESULTS
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CONCLUSIONS
F. nucleatum induces tumour cell proliferation1
F. nucleatum-FadA adhesin binds to E-cadherin aided by Annexin A1,
which is specifically expressed in proliferating CRC cells. The binding
results in a phosphorylation cascade leading to β-catenin accumulation
in the cytoplasm and translocation into the nucleus (Fig. 3). Once in the
nucleus the β-catenin-regulated transcription (CRT) is activated.
Consequently, there is an overexpression of oncogenes such as CCND1
(Cyclin D1 ) and MYC (c-Myc) genes that induce CRC growth[5, 6].
Figure 3. In cancerous cells Annexin A1 level increases, FadA binding 
enhances, FadA–E-cadherin–Annexin A1–β-catenin complex forms,     
β-catenin is activated, resulting in acceleration of cancer progression.
F. nucleatum modulates the tumour immune environment
Selectively recruits tumour infiltrating myeloid cells
Differentiated CD11b+ tumour infiltrating myeloid cells (TIMs) play an 
important role in promoting tumour progression and angiogenesis [3].  
Suppresses anti-tumour immunity
• Inhibition via TIGIT receptor:
Fap2 protein interacts with TIGIT,
thus delivering and inhibitory
signal throughout ITIM and ITT
domains[7].
• Inhibition via CEACAM1 receptor:
an unknown F. nucleatum ligand,
different from Fap2 protein, binds
and activates the inhibitory
receptor CEACAM1[8].
F. nucleatum directly inhibits the activity of tumour-infiltrating lymphocytes 
(TILs), i.e. NK, CD4+, CD8+, via two inhibitory immune cell receptors (Fig. 5): 
• Myeloid-derived suppressor cells: 
Monocytic (M)-MDSC and Granulocytic 
(G)-MDSC
• Tumour-associated macrophages and 
M2-like TAMs
• Tumour-associated neutrophils (TANs)
• Dendritic cells: classical myeloid and 
CD103+ regulatory DCs 
Figure 4. Representative image of TIMs in
CRC and their suggested modulation of the
immune response to tumour.
Figure 5. Schematic representation of the Fap2-dependent
and Fap2-independent mechanisms to inhibit TILs activities
via TIGIT and CEACAM1 inhibitory receptors.
Intratumoural F. nucleatum strains may have an oral origin as patients with
F. nucleatum-positive CRC have oral and tumoural F. nucleatum strains
that share matching arbitrarily primed PCR strain-typing patters[1].
Significantly elevated levels of F. nucleatum are found in CRC tissues. The
interaction between Gal-GalNAc host polysaccharide, overexpressed in CRC
cells, and Fap2 fusobacterial lectin could explicate F. nucleatum
enrichment in CRC tissues (Fig. 1)[2].
Figure 1. Representation of Fap2-mediated enrichment of F. nucleatum 
in CRC tissue. Healthy colon does not overexpress Gal-GalNAc.
ORIGIN OF F. nucleatum TUMOURAL STRAINS AND ENRICHMENT IN CRC TISSUE
F. nucleatum possible routes to reach CRC tissue to exert its effects:
• Oral-gastrointestinal route: mice fed with F. nucleatum harbour
the bacterium in their large intestine tumours[3].
• Hematogenous route: F. nucleatum-FadA adhesin colocalizes with
vascular endothelial (VE)-cadherin and allows F. nucleatum to
cross the endothelium through loosened junctions (Fig. 2)[4].
Figure 2. Exemplification of how FadA adhesin binds VE-cadherin and 
alters endothelial integrity allowing F. nucleatum to cross the endothelium.   
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A chronic proinflammatory tumour environment favours tumorigenesis.
F. nucleatum-associated CRC gene expression signature is enriched for the
inflammatory response gene ontology category. This gene expression
profile is suggestive of an NF-kappaB-driven proinflammatory response.
Indeed, NF-κB signalling pathway is more activated in human CRC samples
with high vs low Fusobacterium spp. abundance. Experimental evidence
suggests that FadA binding to E-cadherin and subsequent internalization
via clathrin is necessary for NF-kB signalling pathway activation[3, 5].
The involvement of F. nucleatum in CRC carcinogenesis is still at the stage of association. Yet, in this review, three examples of F. nucleatum possible
oncogenic mechanisms have been discussed and could be considered the three axis of F. nucleatum role in CRC progression. However, these mechanisms
surely demonstrate just a glimpse of the diverse ways by which F. nucleatum could promote a protumourigenic environment. Hence, findings to date are not
enough to determine with certainty the clinical prognosis of F. nucleatum – positive CRC cases. Thus, robust experimental approaches, be it within human
cohorts or preclinical models, along with reproducible results across microbiota studies are crucial to bridge the translational gap, and to ensure that data are
neither lost in translation nor mistranslated clinically.
• IL1 β • TNF-α• IL12 • IL6 • IL8 • TGF-β • COX-2
Colorectal cancer (CRC) is the third most commonly diagnosed neoplasm of the
gastrointestinal tract and the second cause of cancer death. In the past years, sequencing
studies in human tumour tissues and stools specimens, along with functional studies in
animal models have recognized the possible role of F. nucleatum in colorectal carcinogenesis.
F. nucleatum generates proinflammatory tumour environment
The additive effect of both F. nucleatum
ligands helps cancer evade immune cell
attack and enables tumour progression.
Subsets of TIMs are increased in 
intestinal tumours of ApcMin/+ mice fed 
with F. nucleatum (Fig. 4)[3] :
